Holen Sie sich die Stockscreener-App
509.13
0.49%
2.465
Schlusskurs vom Vortag:
$506.67
Offen:
$506.67
24-Stunden-Volumen:
185.95K
Relative Volume:
0.40
Marktkapitalisierung:
$40.11B
Einnahmen:
$4.45B
Nettoeinkommen (Verlust:
$1.10B
KGV:
37.46
EPS:
13.591
Netto-Cashflow:
$1.06B
1W Leistung:
-1.66%
1M Leistung:
-2.13%
6M Leistung:
-13.97%
1J Leistung:
-19.17%
1-Tages-Spanne:
$506.12
$514.51
1-Wochen-Bereich:
$501.17
$531.38
52-Wochen-Spanne:
$500.61
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, NTRA, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
509.13 | 40.11B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
639.81 | 236.57B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
213.38 | 150.00B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
387.56 | 55.87B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
164.54 | 46.39B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
424.33 | 41.69B | 3.77B | 449.25M | 240.68M | 7.8556 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Neutral |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-31 | Hochstufung | Stifel | Hold → Buy |
| 2025-10-01 | Eingeleitet | UBS | Neutral |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-01 | Eingeleitet | Jefferies | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
Analysts keep Moderate Buy on IDEXX Laboratories stock - AD HOC NEWS
IDEXX Laboratories stock after-hours at EUR 469.60: plus 1.94 percent versus prior close - AD HOC NEWS
IDEXX sets November 2 results date and IDEXX Laboratories stock costs EUR 462.25 - AD HOC NEWS
IDEXX Laboratories, Inc. Revenue Breakdown – XETR:IX1 - TradingView
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo Finance
IDEXX Laboratories to Release 2026 Third Quarter Financial Results - Business Wire
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo Finance
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo! Finance Canada
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories Acquires Veterinary AI Platform CoVetAI - Yahoo Finance
Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories - PR Newswire
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1%SNS Insider - GlobeNewswire Inc.
IDEXX Laboratories stock falls 1.65 percent below USD 747 target - AD HOC NEWS
IDEXX Laboratories stock heads into the open after September 24 update - AD HOC NEWS
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history - Yahoo Finance Singapore
IDEXX Laboratories, Inc. (IDXX) Stock Price, News, Quote & History - Yahoo! Finance Canada
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo! Finance Canada
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history - Yahoo Finance Australia
Should You Continue to Hold IDXX Stock in Your Portfolio? - TradingView
IDEXX Laboratories Acquires CoVetAI to Enhance Veterinary Software Ecosystem - Global Legal Chronicle
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories stock gains 1.16 percent as valuation holds - AD HOC NEWS
IDEXX Laboratories stock heads into the open after recent gains - AD HOC NEWS
Recent acquisitions: IDEXX buys CoVet, The Farmer's Dog acquires Woof - DVM360
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets - Yahoo Finance
IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference - Yahoo Finance
IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics - Yahoo Finance
IDEXX Laboratories Inc | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide - Yahoo Finance
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence - Vet Candy
IDEXX Stock Gains Following the Acquisition of CoVet - Your Wyoming Link
IDEXX Stock Gains Following the Acquisition of CoVet - Yahoo Finance
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection - Business Wire
IDEXX Laboratories (IDXX) Could Be 29% Below Fair Value As Diagnostics Growth Stays In Focus - finance.yahoo.com
UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Maintains Target Price $670 - Moomoo
IDEXX Laboratories (IDXX) Looks 19.8% Undervalued on GF Value™ - GuruFocus
IDEXX Laboratories Acquires Veterinary AI Software Firm CoVetAI - marketscreener.com
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence - Business Wire
IDXX - Finviz
IDEXX Laboratories stock gains as analysts lift targets - ad-hoc-news.de
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IDEXX Laboratories stock reacts to insider share sale and recent earnings strength - ad-hoc-news.de
Engaging In Options Activity, Lawrence D Kingsley Exercises Options Valued At $873K In IDEXX Laboratories - Benzinga
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock - The Motley Fool
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock - Yahoo Finance
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Idexx Laboratories Inc-Aktie (IDXX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LAWRENCE D KINGSLEY | Director |
Sep 04 '26 |
Proposed Sale |
532.08 |
2,203 |
1,172,178 |
0 |
| Kingsley Lawrence D | Director |
Sep 04 '26 |
Sale |
532.08 |
2,203 |
1,172,178 |
9,568 |
| Emerson Andrew | EVP, CFO and Treasurer |
Aug 20 '26 |
Option Exercise |
178.26 |
265 |
47,239 |
4,507 |
| FENNELL GEORGE | Executive Vice President |
Jun 01 '26 |
Option Exercise |
0.00 |
639 |
0 |
10,717 |
| Margaret Anne Szostak | Director |
May 20 '26 |
Proposed Sale |
553.58 |
1,344 |
744,012 |
0 |
| Kingsley Lawrence D | Director |
May 07 '26 |
Option Exercise |
0.00 |
339 |
0 |
9,568 |
| Peacock Karen | Director |
May 07 '26 |
Option Exercise |
0.00 |
101 |
0 |
102 |
| HOOLEY JOSEPH L | Director |
May 07 '26 |
Option Exercise |
0.00 |
158 |
0 |
276 |
| Vandebroek Sophie V. | Director |
May 07 '26 |
Option Exercise |
0.00 |
257 |
0 |
905 |
| JUNIUS DANIEL M | Director |
May 07 '26 |
Option Exercise |
0.00 |
257 |
0 |
3,561 |
2.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):